Skip to search formSkip to main contentSkip to account menu

ciprofibrate

Known as: 2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid, 2-(P-(2,2-Dichlorocyclopropyl)Phenoxy)-2-Methylpropionic Acid, Propanoic Acid, 2-(4-(2,2-Dichlorocyclopropyl)Phenoxy)-2-Methyl- 
A fibrate derivative with antilipidemic activity.
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Clofibric AcidFibric AcidsHypolipidemic AgentsPeroxisome Proliferators

Narrower (2)

LipanorOroxadin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study
Abstract Several therapeutic agents and industrial chemicals induce liver tumors in rodents through the activation of the… 
Review
2006
Review
2006
PPARs, Obesity, and Inflammation
The worldwide prevalence of obesity and related metabolic disorders is rising rapidly, increasing the burden on our healthcare… 
Highly Cited
2004
Highly Cited
2004
Application of comparative functional genomics to identify best-fit mouse models to study human cancer
Genetically modified mice have been extensively used for analyzing the molecular events that occur during tumor development. In… 
Highly Cited
2000
Highly Cited
2000
Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*
Fibrates and glitazones are two classes of drugs currently used in the treatment of dyslipidemia and insulin resistance (IR… 
Highly Cited
2000
Highly Cited
2000
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
BACKGROUND Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced… 
Highly Cited
1997
Highly Cited
1997
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Highly Cited
1994
Highly Cited
1994
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.
Highly Cited
1993
Highly Cited
1993
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.
Review
1990
Review
1990
Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Fenofibrate is a lipid-regulating drug which is structurally related to other fibric acid derivatives, such as clofibrate. At the… 
Highly Cited
1988
Highly Cited
1988
Inhibitors of cytochrome P-450-dependent arachidonic acid metabolism.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)